{"gene":"CYP11A1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1986,"finding":"P450scc (CYP11A1) is the single enzyme mediating conversion of cholesterol to pregnenolone (20,22-desmolase activity) in human steroidogenesis; its mRNA accumulation in granulosa cells is stimulated in a dose-dependent, cAMP-mediated manner by hCG and FSH, indicating gonadotropin-specific transcriptional regulation.","method":"Northern blot hybridization with 32P-labeled P450scc cDNA; progesterone secretion assay; hormone dose-response in primary human granulosa cell cultures","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct mRNA quantification plus functional secretion assay, multiple hormonal conditions, replicated across labs in subsequent work","pmids":["3011839"],"is_preprint":false},{"year":1990,"finding":"The bovine CYP11A1 promoter contains a cAMP-responsive region between -186 and -101 bp that functions independently of canonical CRE sequences; sequences between -183 and -83 bp drive both basal and cAMP-enhanced transcription when fused to a heterologous promoter in adrenocortical cells.","method":"Deletion mutagenesis of the 5'-flanking region linked to a reporter gene; transient transfection into mouse Y1 adrenal tumor cells and primary bovine adrenocortical cells; primer extension for transcription start site mapping","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic deletion mutagenesis with reporter gene in two steroidogenic cell systems","pmids":["2154474"],"is_preprint":false},{"year":1992,"finding":"A G-rich sequence element at -118 to -100 bp in the bovine CYP11A promoter binds an Sp1-related protein and overlaps with a putative adrenal-specific protein binding site; deletion of this minimal cAMP-responsive sequence abolishes cAMP-dependent reporter gene transcription in Y1 cells.","method":"DNase I footprinting, electrophoretic mobility shift assay (EMSA), competition analysis, reporter gene transfection into Y1 adrenocortical cells","journal":"Molecular Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EMSA with competition plus functional reporter assays, minimal sequence mapped","pmids":["1333053"],"is_preprint":false},{"year":1992,"finding":"Transfer of cholesterol to the inner mitochondrial membrane–bound CYP11A1 is the rate-limiting step in steroid synthesis; cholesterol supply involves cytoskeletal elements and sterol carrier protein-2 (SCP2) for outer membrane delivery, and steroidogenesis activator peptide plus GTP facilitate inner-to-outer membrane cholesterol transfer.","method":"Cell fractionation, inhibitor studies, reconstitution of mitochondrial cholesterol transfer with defined factors, digitonin solubilization of outer mitochondrial membranes","journal":"The Journal of Steroid Biochemistry and Molecular Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical approaches in the same review/study, but partly a review compiling earlier work","pmids":["22217822"],"is_preprint":false},{"year":1992,"finding":"cAMP-dependent regulation of CYP11A1 mRNA in JEG-3 cytotrophoblast cells is principally transcriptional (as shown by RNA polymerase run-on assays), whereas adrenodoxin mRNA regulation is posttranscriptional and not mediated by the AUUUA sequences in its 3'-UTR.","method":"Chimeric vector transfection with swapped 3'-UTRs; RNA polymerase run-on assay; actinomycin-D mRNA stability assay; cycloheximide treatment","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — run-on assay directly demonstrated transcriptional regulation; multiple orthogonal methods (chimeric constructs, stability assay, transcription run-on)","pmids":["1446636"],"is_preprint":false},{"year":1993,"finding":"The steroidogenic cell-specific transcription factor Ad4BP (SF-1) activates the CYP11A1 (CYP11A) gene through an Ad4 cis-element in both adrenal and Leydig cells; activation is potentiated by the cAMP pathway via protein kinase A and is absent in nonsteroidogenic cells lacking Ad4BP.","method":"Reporter gene constructs with combinations of Ad1/Ad4 cis-elements; transient transfection into Y1, I-10, and PC-12 cells; cotransfection of Ad4BP expression vector; immunoblot for Ad4BP","journal":"Molecular Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic promoter element analysis plus gain-of-function with Ad4BP expression vector, multiple cell types","pmids":["8247022"],"is_preprint":false},{"year":1993,"finding":"CYP11A1 fusion proteins with adrenodoxin reductase and adrenodoxin (P450scc-AdRed-Adx triple fusion) achieve substantially higher pregnenolone production than triple transfection of individual components, demonstrating that physical linkage of the Type I electron transfer chain components enhances catalytic efficiency.","method":"Construction of fusion protein expression vectors by PCR/cassette assembly; transfection into COS-1 cells; pregnenolone secretion assay using 22R-hydroxycholesterol substrate","journal":"DNA and Cell Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct enzymatic activity assay with engineered fusion proteins and comparison to wild-type triple transfection","pmids":["8517924"],"is_preprint":false},{"year":1994,"finding":"The human CYP11A1 gene contains a proximal cAMP-responsive sequence (P-CRS) active in both adrenal Y1 and placental JEG-3 cells, and an upstream CRS (U-CRS, -1621 to -1503) plus an enhancer (-1931 to -1822) that function only in Y1 cells; U-CRS-mediated cAMP response requires protein kinase A, whereas P-CRS does not.","method":"Deletion analysis with reporter gene constructs; transient transfection into Y1 and JEG-3 cells; protein kinase A-deficient cell line; DNase I footprinting; gel mobility shift and antibody supershift","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic deletion mutagenesis, PKA-deficient cells, and DNA-protein interaction assays","pmids":["8119986"],"is_preprint":false},{"year":1994,"finding":"CREB/ATF proteins and Ad4BP (SF-1) bind to closely arranged CRE-like and Ad4 sequences in the upstream CYP11A1 regulatory region and act synergistically to confer cAMP-responsive, steroidogenic cell-specific expression.","method":"DNase I footprinting with bovine adrenal nuclear extracts; point mutation analysis; reporter gene transfection","journal":"European Journal of Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — footprinting plus point mutagenesis with functional reporter assays","pmids":["8026494"],"is_preprint":false},{"year":1994,"finding":"An upstream element (AdE) in the human CYP11A1 gene containing two protein binding regions (AdE1 and AdE2) that bind NF1- and Sp1-like proteins enhances CYP11A1 expression specifically in steroidogenic cells; AdE1 and AdE2 act combinatorially for full activity.","method":"EMSA, footprinting, competition, antibody supershift; mutagenesis of binding sites; reporter gene transfection into steroidogenic and nonsteroidogenic cell lines","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal DNA-protein interaction methods plus functional transfection data","pmids":["8703023"],"is_preprint":false},{"year":1995,"finding":"Two Sp1-binding sites at -111/-100 bp and -70/-50 bp in the bovine CYP11A promoter are necessary for both basal and cAMP-dependent transcription; mutations eliminating Sp1 binding at -111/-100 markedly reduce cAMP-induced transcription via the protein kinase A pathway.","method":"EMSA with purified Sp1; anti-Sp1 antibody supershift; mutation analysis; reporter gene transfection into Y1 adrenal cells","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — purified Sp1 binding confirmed, mutation-function correlation established in adrenal cells","pmids":["7592707"],"is_preprint":false},{"year":1998,"finding":"Human CYP11A1 expressed in E. coli retains catalytic activity comparable to placenta-purified enzyme; mutation of Ile-462 to Leu decreases kcat with cholesterol and increases Km for 22R-hydroxycholesterol but not for 20α-hydroxycholesterol, indicating that Ile-462 resides near the side-chain binding site.","method":"Recombinant expression in E. coli; enzyme purification; kinetic assays (Km, Vmax, kcat) with cholesterol and hydroxycholesterol substrates; site-directed mutagenesis","journal":"Archives of Biochemistry and Biophysics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic characterization plus mutagenesis with substrate specificity readout","pmids":["9578606"],"is_preprint":false},{"year":1999,"finding":"Sp1 alone is sufficient to confer cAMP-dependent transcriptional activation of CYP11A1 through the -118/-100 element; Sp3 does not repress Sp1-dependent activation at this promoter, unlike other GC-rich promoters.","method":"Drosophila SL2 cells lacking endogenous Sp factors; cotransfection of Sp1, Sp3, Sp4 expression vectors with CYP11A reporter; cotransfection of PKA catalytic subunit; mutation of -118/-100 element","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — use of Sp-negative SL2 cells with reconstitution is a clean gain-of-function approach","pmids":["10383457"],"is_preprint":false},{"year":1999,"finding":"Positively charged residues K403, K405, and R426 on the proximal surface of bovine P450scc (CYP11A1) are required for electrostatic interaction with adrenodoxin; R426Q mutation completely abolishes adrenodoxin binding while retaining CO-binding and chemical reducibility.","method":"Site-directed mutagenesis of 13 P450scc variants; adrenodoxin binding assay; reduction kinetics; enzymatic activity measurement; molecular modeling and docking","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of multiple residues with functional characterization (binding, reduction, activity) plus structural modeling","pmids":["12081479"],"is_preprint":false},{"year":2001,"finding":"Adrenodoxin mutants with C-terminal truncation and introduction of a tryptophan residue (S112W) form more stable complexes with CYP11A1, show faster reduction rates, and achieve ~100-fold increased efficiency in cholesterol-to-pregnenolone conversion, demonstrating that adrenodoxin–CYP11A1 complex stability directly determines catalytic throughput.","method":"Site-directed mutagenesis of adrenodoxin; kinetic measurement of CYP11A1·CO complex formation; cholesterol conversion assay","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinetics with multiple mutants and quantitative activity measurement","pmids":["11459837"],"is_preprint":false},{"year":2002,"finding":"Cyp11a1 null mice completely lack steroid synthesis, die shortly after birth (rescued by steroid injection), develop ectopic Cyp21 expression in the testis due to absence of glucocorticoid feedback, and exhibit feminization of XY males—establishing CYP11A1 as essential for the first and obligatory step of all steroid hormone biosynthesis.","method":"Targeted gene disruption (neo insertion into exon 1); steroid measurements; hormonal rescue experiments; histological analysis of adrenals/gonads; RT-PCR for ectopic gene expression","journal":"Molecular Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete KO with multiple phenotypic readouts, hormonal rescue, and ectopic gene expression analysis","pmids":["12145347"],"is_preprint":false},{"year":2002,"finding":"A compound heterozygous CYP11A1 mutation (R353W + A189V/splicing) causes partial P450scc deficiency in humans; R353W markedly reduces enzymatic activity, demonstrating that Arg353 is a crucial residue for catalytic function.","method":"Sequencing of CYP11A1; site-directed mutagenesis to recreate mutations in F2 fusion protein; pregnenolone production assay in transfected COS-1 cells","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional enzyme assay directly linked to patient phenotype","pmids":["12161514"],"is_preprint":false},{"year":2003,"finding":"Purified CYP11A1 (P450scc) reconstituted with adrenodoxin and adrenodoxin reductase hydroxylates vitamin D3 to produce 20-hydroxyvitamin D3 and 20,22-dihydroxyvitamin D3 as major products, and converts 7-dehydrocholesterol to 7-dehydropregnenolone—identifying a vitamin D hydroxylation pathway distinct from classical 1α/25-hydroxylation.","method":"In vitro reconstituted system with purified CYP11A1, adrenodoxin, adrenodoxin reductase; NADPH-dependent metabolism assay; product identification by MS and comparison with standards","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — fully reconstituted in vitro system with purified components, product identification by MS; replicated in subsequent studies","pmids":["14657394"],"is_preprint":false},{"year":2003,"finding":"The F-G loop region (residues V212 and L219) of CYP11A1 becomes localized to a hydrophobic environment upon membrane binding, as shown by fluorescent probe blue-shift, indicating that CYP11A1 has a monotopic association with the phospholipid membrane mediated at least in part through the F-G loop.","method":"Hydrophobicity profiling; A'-helix deletion mutagenesis; cysteine-scanning mutagenesis (L24C, V212C, L219C) with NBD fluorescent labeling; fluorescence blue-shift assay with phospholipid vesicles; tryptophan quenching by acrylamide","journal":"Biochimica et Biophysica Acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis combined with fluorescence spectroscopy in membrane-binding assay, multiple residues tested","pmids":["14637024"],"is_preprint":false},{"year":2004,"finding":"P450scc enzyme and its electron transfer partners (adrenodoxin, adrenodoxin reductase, MLN64) are expressed and functionally active in skin mitochondria; purified P450scc and placental/adrenal mitochondria convert 7-dehydrocholesterol to 7-dehydropregnenolone with kinetics similar to cholesterol conversion.","method":"RT-PCR and immunoblot for P450scc system components in skin cells; functional assay of 7-DHC conversion in isolated skin mitochondria; product identity confirmed by NMR, MS, and comparison with synthetic standard","journal":"European Journal of Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity demonstrated in isolated organelles; product identity confirmed by multiple analytical methods","pmids":["15511223"],"is_preprint":false},{"year":2006,"finding":"CYP11A1 metabolizes vitamin D2 in a reconstituted system to produce 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2; adrenal mitochondria also metabolize vitamin D2 with this pathway inhibited by the CYP11A1 inhibitor aminoglutethimide, confirming CYP11A1 as responsible.","method":"Reconstituted P450scc system; NMR structure determination of products; adrenal mitochondria metabolism with pharmacological inhibitor control; keratinocyte DNA synthesis assay","journal":"The FEBS Journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted system with NMR product identification plus mitochondrial inhibition control","pmids":["16817851"],"is_preprint":false},{"year":2007,"finding":"HIPK3 and c-Jun are required for basal and cAMP-stimulated CYP11A1 expression; cAMP stimulation leads to HIPK3-mediated phosphorylation of JNK and c-Jun, and these phosphorylation events enhance SF-1 transcriptional activity for CYP11A1.","method":"Cotransfection/overexpression of HIPK3 and c-Jun; siRNA knockdown; luciferase reporter assay; phosphorylation detection; SF-1 activity assays in adrenal/gonadal cells","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain-of-function and loss-of-function with defined phosphorylation readout and reporter gene assay","pmids":["17210646"],"is_preprint":false},{"year":2008,"finding":"CYP11A1 hydroxylates vitamin D3 sequentially in phospholipid vesicles producing 20(OH)D3 then 20,23(OH)2D3 then 17,20,23(OH)3D3; the Km for vitamin D3 in vesicles is 3.3 mol/mol phospholipid, with StAR protein stimulating vitamin D3 exchange between vesicles.","method":"Reconstituted membrane-bound P450scc kinetics; gel filtration of vesicles; sequential product identification; N-62 StAR protein addition assay","journal":"The International Journal of Biochemistry & Cell Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — detailed kinetic characterization with reconstituted membrane system and StAR protein","pmids":["18573681"],"is_preprint":false},{"year":2010,"finding":"Mutation of the proximal SF-1-binding site in the Cyp11a1 promoter in vivo causes downregulation of CYP11A1 in the adrenal and testis but not in the ovary and placenta, resulting in attenuated corticosterone circadian rhythms and blunted stress response.","method":"Transgenic mouse with mutated SF-1-binding site driving reporter gene; endogenous gene expression analysis; corticosterone measurements under stress","journal":"Molecular and Cellular Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic/knock-in mutation with tissue-specific and physiological phenotype readouts","pmids":["21195129"],"is_preprint":false},{"year":2010,"finding":"A novel CYP11A1 missense mutation A269V retains 11% of wild-type P450scc activity and causes nonclassic lipoid congenital adrenal hyperplasia when compound heterozygous with a frameshift mutation, establishing a direct genotype-activity-phenotype relationship.","method":"Sequencing; site-directed mutagenesis recreating mutations in F2 fusion protein; pregnenolone production assay (Vmax/Km) in transfected COS-1 cells","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative in vitro enzyme assay with mutagenesis directly linked to clinical phenotype","pmids":["21159840"],"is_preprint":false},{"year":2011,"finding":"CYP11A1 produces 22-hydroxyvitamin D3 and 20,22-dihydroxyvitamin D3 as additional products of vitamin D3 metabolism; these 22-hydroxy derivatives are biologically active on keratinocytes via the vitamin D receptor (VDR), stimulating VDR translocation to the nucleus and inhibiting proliferation.","method":"Reconstituted P450scc reaction; NMR structure determination; purified 22(OH)D3 as substrate for further P450scc action; keratinocyte proliferation/differentiation assays; VDR translocation immunofluorescence","journal":"Drug Metabolism and Disposition","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted enzymatic system with NMR, plus cellular VDR activity assays; builds on replicated prior work","pmids":["21677063"],"is_preprint":false},{"year":2013,"finding":"CYP11A1 overexpression in trophoblastic cells reduces proliferation and induces apoptosis via activation of caspase-3; in preeclampsia placenta, CYP11A1 is significantly upregulated at both mRNA and protein levels.","method":"CYP11A1 overexpression in HTR8/SVneo trophoblastic cells; TUNEL staining for apoptosis; caspase-3 activation assay; RT-PCR and Western blot in patient tissue","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression with defined apoptosis readout but single method for cellular mechanism","pmids":["23555723"],"is_preprint":false},{"year":2013,"finding":"Cyp11a1 enzymatic activity in CD8+ T cells is required for IL-4-induced conversion from IFN-γ to IL-13 production; inhibition with aminoglutethimide or shRNA knockdown prevents this phenotypic conversion without affecting T-bet or GATA3 expression.","method":"Aminoglutethimide pharmacological inhibition; shRNA knockdown of Cyp11a1; cytokine measurement by ELISA/RT-PCR; adoptive transfer into CD8-deficient recipients; airway hyperresponsiveness measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function by two orthogonal methods (inhibitor + shRNA) with in vivo adoptive transfer confirmation","pmids":["23630275"],"is_preprint":false},{"year":2013,"finding":"Cyp11a1 inhibition (aminoglutethimide) prevents peanut-induced allergic diarrhea and intestinal inflammation; shRNA silencing in polarized TH2 CD4+ T cells reduces pregnenolone and IL-13, establishing that Cyp11a1 steroidogenic activity is required for TH2 cytokine production.","method":"In vivo aminoglutethimide treatment in peanut sensitization/challenge model; shRNA silencing in polarized T cells; pregnenolone ELISA; IL-13/IL-17A mRNA and protein quantification","journal":"The Journal of Allergy and Clinical Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two orthogonal loss-of-function methods (pharmacological + shRNA), in vivo and in vitro confirmation","pmids":["23870673"],"is_preprint":false},{"year":2013,"finding":"Overexpression of Cyp11a1 in transgenic mice disrupts normal corpus luteum development, causes progesterone insufficiency during early pregnancy (delayed steroidogenic gene activation, elongated mitochondria, lipid accumulation), and leads to impaired implantation, anomalous placentation, and delayed parturition.","method":"BAC transgenic mice with extra Cyp11a1 copies; progesterone ELISA; luteal cell morphology (mitochondrial imaging); gene expression analysis; P4 supplementation rescue","journal":"Biology of Reproduction","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain-of-function in vivo model with hormonal, morphological, and developmental phenotype readouts plus rescue experiment","pmids":["23966322"],"is_preprint":false},{"year":2013,"finding":"Seven CYP11A1 missense mutations causing P450scc deficiency were characterized; mutations including Phe215Ser retain only 2.5% and Val415Glu/c.835delA lack detectable enzymatic activity, while Ala269Val retains 12%—directly correlating residue identity with catalytic competence.","method":"CYP11A1 sequencing; site-directed mutagenesis recreating mutations in F2 fusion protein; pregnenolone production assay in transfected COS-1 cells with apparent kinetic parameters","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative enzyme assay for multiple mutants with kinetic parameters","pmids":["23337730"],"is_preprint":false},{"year":2014,"finding":"CYP11A1 metabolizes lumisterol 3 (L3) to produce 24-hydroxy-L3, 22-hydroxy-L3, and 20,22-dihydroxy-L3 as major products, plus pregnalumisterol from side-chain cleavage; this metabolism was confirmed in pig adrenal fragments by LC/MS, establishing a new CYP11A1 substrate pathway.","method":"Reconstituted bovine and human CYP11A1 incubation with L3; NMR structure determination of products; pig adrenal fragment assay; LC/MS product detection","journal":"The International Journal of Biochemistry & Cell Biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted system with purified human and bovine enzyme, NMR confirmation, and tissue validation","pmids":["25130438"],"is_preprint":false},{"year":2014,"finding":"Artemisinins directly target LONP1, enhance the LONP1–CYP11A1 physical interaction, and facilitate LONP1-catalyzed proteolytic degradation of CYP11A1 protein, thereby reducing androgen biosynthesis; LONP1 overexpression alone replicates the androgen-lowering effect.","method":"Target identification of artemisinins binding LONP1; co-immunoprecipitation of LONP1-CYP11A1 complex; CYP11A1 protein degradation assay; LONP1 overexpression; androgen measurements in rodent PCOS models and human patients","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, gain-of-function with LONP1 overexpression, pharmacological validation in vivo and clinical study","pmids":["38870290"],"is_preprint":false},{"year":2016,"finding":"CYP11A1 in steroidogenic cell mitochondria affects mitochondrial morphology; steroidogenic cells exhibit tubular-vesicular cristae (distinct from lamellar cristae in non-steroidogenic cells), and the presence of steroidogenic enzymes in the inner mitochondrial membrane is linked to this morphological feature and degree of cell differentiation.","method":"Electron microscopy of steroidogenic vs. non-steroidogenic mitochondria; correlation with Cyp11a1 transgenic mouse studies showing elongated mitochondria upon overexpression","journal":"Molecular and Cellular Endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — morphological observations corroborated by transgenic overexpression data, but no direct mechanistic experiment linking CYP11A1 activity to cristae shape","pmids":["27815210"],"is_preprint":false},{"year":2018,"finding":"The common CYP11A1 variant p.E314K (rs6161, predicted benign) causes missplicing, produces a nonfunctional protein in mammalian cells, and is a major cause of primary adrenal insufficiency when compound heterozygous with other CYP11A1 variants.","method":"Next-generation sequencing; in silico splicing prediction; in vitro minigene splicing assay; E. coli enzyme activity assay (showed no loss-of-function); mammalian cell transfection to demonstrate nonfunctional protein; cycloheximide chase not mentioned but splicing assay central","journal":"Journal of the Endocrine Society","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro splicing assay combined with mammalian cell functional study demonstrating nonfunctional protein, orthogonal to E. coli assay","pmids":["30620006"],"is_preprint":false},{"year":2019,"finding":"CYP11A1 variant p.E314K causes ~50% decreased protein half-life (increased turnover by cycloheximide chase assay) and retains 60% of wild-type enzymatic activity, establishing that this variant causes primary adrenal insufficiency primarily through impaired protein stability rather than catalytic loss.","method":"HEK293T transfection; cycloheximide chase assay for protein stability; pregnenolone production assay from p.E314K-F2 fusion protein in COS-1 cells","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — protein stability and enzymatic activity measured by orthogonal in vitro methods","pmids":["30299480"],"is_preprint":false},{"year":2022,"finding":"Human glial cells produce pregnenolone via a mitochondrial CYP450 enzyme other than CYP11A1; pregnenolone synthesis in glial cells is not inhibited by CYP11A1 inhibitors (aminoglutethimide, ketoconazole) and is not altered by overexpression of CYP11A1 isoform b, but is inhibited by ferredoxin reductase knockdown—indicating a different mitochondrial P450.","method":"Mass spectrometry and ELISA for pregnenolone; pharmacological inhibition (aminoglutethimide, ketoconazole); CYP11A1 isoform b overexpression; siRNA knockdown of NADPH-cytochrome P450 reductase and ferredoxin reductase; ROS modulation","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — negative result for CYP11A1 established by multiple orthogonal approaches (inhibitors, overexpression, siRNA), pointing to alternative enzyme","pmids":["35688208"],"is_preprint":false},{"year":2021,"finding":"Antiproliferative and antifibrotic activities of CYP11A1-derived vitamin D3 hydroxyderivatives (20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3) in skin fibroblasts are dependent on functional RORγ; these effects are reversed or abolished in RORγ knockout fibroblasts.","method":"Wild-type, heterozygous, and RORγ knockout murine fibroblasts; proliferation assay; TGF-β1-induced collagen synthesis assay; RNA-seq transcriptome analysis","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function (KO) with dose-response assays and transcriptomic validation across three genotypes","pmids":["33107570"],"is_preprint":false},{"year":2023,"finding":"ODM-208, a novel CYP11A1 inhibitor, potently suppresses steroid hormone biosynthesis (testosterone to undetectable levels in 87% of patients within one week) in metastatic castration-resistant prostate cancer patients, confirming that CYP11A1 catalytic activity is the primary source of residual androgen biosynthesis in this disease setting.","method":"Phase 1/2 clinical trial; pharmacodynamic measurement of circulating testosterone and other steroids; PSA response measurement; adrenal insufficiency as on-target toxicity","journal":"NEJM Evidence","confidence":"High","confidence_rationale":"Tier 2 / Strong — prospective clinical pharmacodynamics in 92 patients with target-defined hormone suppression","pmids":["38320513"],"is_preprint":false}],"current_model":"CYP11A1 (P450scc) is a mitochondrial inner-membrane cytochrome P450 that receives electrons from NADPH via adrenodoxin reductase and adrenodoxin—interacting through electrostatic contacts at residues K403, K405, and R426—to catalyze the rate-limiting, three-step conversion of cholesterol to pregnenolone (the obligatory first step of all steroidogenesis), and additionally hydroxylates alternative sterol substrates including 7-dehydrocholesterol, vitamin D3/D2, and lumisterol to bioactive metabolites; its transcription in steroidogenic tissues is driven by the cAMP–PKA pathway through SF-1, Sp1, HIPK3/JNK/c-Jun, and tissue-specific enhancer elements, while its protein stability and activity are regulated post-translationally by LONP1-mediated proteolysis, and its enzymatic activity in immune cells (CD8+ T cells, TH2 cells) and skin is required for context-specific steroidogenic and immunomodulatory functions."},"narrative":{"mechanistic_narrative":"CYP11A1 (P450scc) catalyzes the rate-limiting, obligatory first step of all steroid hormone biosynthesis—the side-chain cleavage of cholesterol to pregnenolone—and Cyp11a1-null mice completely lack steroidogenesis, die shortly after birth unless rescued by steroid injection, and show feminization of XY males, establishing the enzyme as indispensable [PMID:3011839, PMID:12145347]. The enzyme is membrane-associated, contacting the phospholipid bilayer in part through its F-G loop [PMID:14637024], and depends on a Type I electron-transfer chain in which adrenodoxin reductase and adrenodoxin deliver NADPH-derived electrons; CYP11A1 engages adrenodoxin through positively charged proximal-surface residues (K403, K405, R426), and the stability of the adrenodoxin·CYP11A1 complex directly sets catalytic throughput [PMID:12081479, PMID:11459837]. Cholesterol delivery to the inner-membrane enzyme is itself rate-limiting and requires sterol transfer machinery and StAR-type proteins [PMID:22217822, PMID:18573681]. Beyond cholesterol, reconstituted CYP11A1 hydroxylates alternative sterol substrates—7-dehydrocholesterol, vitamin D3, vitamin D2, and lumisterol—generating bioactive metabolites such as 20-hydroxyvitamin D3, whose antiproliferative and antifibrotic effects act through nuclear receptors VDR and RORγ [PMID:14657394, PMID:15511223, PMID:16817851, PMID:21677063, PMID:25130438, PMID:33107570]. Transcription in steroidogenic tissues is driven by cAMP–PKA signaling through SF-1/Ad4BP acting combinatorially with CREB/ATF, Sp1, and NF1-like factors at promoter and upstream enhancer elements, with the HIPK3/JNK/c-Jun module potentiating SF-1 activity [PMID:8247022, PMID:8026494, PMID:7592707, PMID:10383457, PMID:17210646]. Post-translationally, CYP11A1 abundance is controlled by LONP1-mediated proteolysis, a mechanism exploited pharmacologically by artemisinins to lower androgen output [PMID:38870290]. Loss-of-function CYP11A1 mutations cause classic and nonclassic lipoid congenital adrenal hyperplasia and primary adrenal insufficiency, with genotype severity tracking residual catalytic activity or protein stability [PMID:12161514, PMID:21159840, PMID:23337730, PMID:30620006]. The enzyme also exerts non-adrenal functions: its steroidogenic activity in CD8+ and TH2 cells is required for IL-13/TH2 cytokine production [PMID:23630275, PMID:23870673], and pharmacological inhibition (ODM-208) confirms CYP11A1 as the source of residual androgens in castration-resistant prostate cancer [PMID:38320513].","teleology":[{"year":1986,"claim":"Established that a single enzyme, P450scc, performs cholesterol-to-pregnenolone conversion in human steroidogenesis and that its expression is hormonally controlled, defining the entry point of steroid synthesis.","evidence":"Northern blot and progesterone secretion assays with hCG/FSH dose-response in primary human granulosa cells","pmids":["3011839"],"confidence":"High","gaps":["Did not define the cis-elements or transcription factors mediating cAMP induction","No structural basis for catalysis addressed"]},{"year":1992,"claim":"Resolved how cholesterol reaches the inner-membrane enzyme, showing that substrate delivery rather than catalysis is the kinetically limiting event in steroidogenesis.","evidence":"Cell fractionation, inhibitor studies, and reconstitution of mitochondrial cholesterol transfer with defined factors","pmids":["22217822"],"confidence":"Medium","gaps":["Partly a review compiling earlier work","Relative contributions of SCP2, StAR-type peptides, and GTP not fully quantified"]},{"year":1994,"claim":"Mapped the cAMP-responsive transcriptional architecture, identifying SF-1/Ad4BP acting with CREB/ATF, Sp1, and NF1-like factors at distinct proximal and upstream elements to confer cell-specific, hormone-inducible CYP11A1 expression.","evidence":"Promoter deletion, footprinting, EMSA/supershift, and reporter transfection across adrenal (Y1), placental (JEG-3), and Sp-negative SL2 cells, plus PKA-deficient lines","pmids":["2154474","1333053","1446636","8247022","8119986","8026494","8703023","7592707","10383457"],"confidence":"High","gaps":["Tissue-specific differences (e.g. placental vs adrenal use of distinct elements) only partially explained","In vivo relevance of individual elements not yet tested"]},{"year":1999,"claim":"Defined the molecular basis of the redox partnership, showing that specific proximal-surface basic residues mediate electrostatic docking of adrenodoxin and that complex stability dictates catalytic efficiency.","evidence":"Site-directed mutagenesis (K403/K405/R426; adrenodoxin S112W), binding/reduction kinetics, cholesterol conversion assays, and molecular docking","pmids":["12081479","11459837"],"confidence":"High","gaps":["No high-resolution co-structure of the human complex in the timeline","Dynamics of electron transfer during the three sequential oxidations not resolved"]},{"year":2002,"claim":"Demonstrated genetically that CYP11A1 is essential and obligatory for all steroidogenesis, and linked human mutations to P450scc-deficiency phenotypes.","evidence":"Cyp11a1 knockout mice with steroid rescue, plus patient mutation analysis recreated in fusion-protein enzyme assays","pmids":["12145347","12161514"],"confidence":"High","gaps":["Did not establish full genotype-phenotype spectrum for partial-activity alleles"]},{"year":2003,"claim":"Revealed that CYP11A1 has a broader substrate range than cholesterol, hydroxylating 7-dehydrocholesterol and vitamin D to novel bioactive metabolites, and clarified its monotopic membrane association.","evidence":"Reconstituted purified-enzyme systems with MS/NMR product identification, plus fluorescent membrane-binding probes on F-G loop residues","pmids":["14657394","14637024"],"confidence":"High","gaps":["Physiological abundance and in vivo roles of these metabolites not established at this stage"]},{"year":2008,"claim":"Extended the alternative-substrate catalogue and characterized sequential hydroxylation kinetics in membranes, identifying vitamin D2 and lumisterol products and StAR-stimulated substrate exchange.","evidence":"Reconstituted membrane-bound kinetics, NMR/LC-MS product identification, tissue (adrenal, pig adrenal, skin mitochondria) validation","pmids":["15511223","16817851","18573681","25130438"],"confidence":"High","gaps":["Quantitative in vivo contribution of CYP11A1 to circulating vitamin D/lumisterol metabolites not measured"]},{"year":2011,"claim":"Connected CYP11A1-derived sterol metabolites to downstream signaling, showing the hydroxyvitamin D products are biologically active through VDR and RORγ.","evidence":"Reconstituted enzymatic production with NMR, keratinocyte/fibroblast proliferation and differentiation assays, VDR translocation imaging, and RORγ knockout fibroblasts","pmids":["21677063","33107570"],"confidence":"High","gaps":["Receptor selectivity among multiple metabolites not fully dissected","In vivo significance in human skin physiology not established"]},{"year":2013,"claim":"Identified non-adrenal immune functions, establishing that CYP11A1 steroidogenic activity in CD8+ and TH2 cells is required for IL-13/TH2 cytokine production and allergic inflammation.","evidence":"Pharmacological inhibition (aminoglutethimide) plus shRNA knockdown, cytokine quantification, adoptive transfer, and in vivo allergy models","pmids":["23630275","23870673"],"confidence":"High","gaps":["Identity of the active steroid metabolite mediating cytokine switching beyond pregnenolone not pinpointed","Mechanism linking steroid output to cytokine gene regulation unresolved"]},{"year":2013,"claim":"Refined the human disease genotype-activity-phenotype relationship and revealed dosage-sensitive reproductive consequences of CYP11A1 levels.","evidence":"Multiple patient missense mutations recreated in fusion-protein enzyme assays with kinetic parameters, plus BAC-transgenic Cyp11a1-overexpressing mice","pmids":["21159840","23337730","23966322","23555723"],"confidence":"High","gaps":["Trophoblast apoptosis mechanism relied on single-method overexpression readout","Causal vs correlative role of CYP11A1 upregulation in preeclampsia not resolved"]},{"year":2019,"claim":"Established that disease can arise through protein-stability defects, not only catalytic loss, exemplified by the missplicing/turnover phenotype of the common p.E314K variant.","evidence":"Minigene splicing assay, mammalian-cell expression, cycloheximide-chase half-life measurement, and fusion-protein activity assays","pmids":["30620006","30299480"],"confidence":"High","gaps":["Cellular machinery degrading the destabilized variant not identified at this stage"]},{"year":2024,"claim":"Identified a post-translational control axis, showing LONP1-mediated proteolysis sets CYP11A1 abundance and that artemisinins exploit this to lower androgen biosynthesis.","evidence":"Target identification of artemisinins, reciprocal LONP1-CYP11A1 co-IP, degradation assays, LONP1 overexpression, and androgen measurements in PCOS models and patients","pmids":["38870290"],"confidence":"High","gaps":["Whether LONP1 degradation is regulated physiologically to tune steroidogenesis not established","Structural basis of LONP1 recognition of CYP11A1 unknown"]},{"year":2023,"claim":"Validated CYP11A1 as a therapeutic target, with the inhibitor ODM-208 abolishing residual androgen biosynthesis in castration-resistant prostate cancer.","evidence":"Phase 1/2 clinical trial with pharmacodynamic steroid measurements and PSA response in 92 patients","pmids":["38320513"],"confidence":"High","gaps":["On-target adrenal insufficiency requires steroid replacement","Durability of response and resistance mechanisms not addressed"]},{"year":null,"claim":"It remains unresolved which steroid metabolite mediates CYP11A1's immunomodulatory and tissue-specific functions and how its substrate selection between cholesterol and alternative sterols is regulated in vivo.","evidence":"No timeline discovery resolves the downstream effector metabolite or in vivo substrate partitioning","pmids":[],"confidence":"Low","gaps":["Effector metabolite in immune cells not identified","In vivo balance between classical steroidogenesis and vitamin D/lumisterol hydroxylation unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,11,17,20,31]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[17,20,25,31]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[18,22]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[3,18,19,33]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,15,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[27,28]}],"complexes":[],"partners":["FDX1","FDXR","LONP1","NR5A1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05108","full_name":"Cholesterol side-chain cleavage enzyme, mitochondrial","aliases":["CYPXIA1","Cholesterol desmolase","Cytochrome P450 11A1","Cytochrome P450(scc)"],"length_aa":521,"mass_kda":60.1,"function":"A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones (PubMed:21636783). Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal (PubMed:21636783). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:21636783)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P05108/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP11A1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP11A1","total_profiled":1310},"omim":[{"mim_id":"614736","title":"GLUCOCORTICOID DEFICIENCY 4 WITH OR WITHOUT MINERALOCORTICOID DEFICIENCY; GCCD4","url":"https://www.omim.org/entry/614736"},{"mim_id":"614647","title":"COENZYME Q6, MONOOXYGENASE; COQ6","url":"https://www.omim.org/entry/614647"},{"mim_id":"613743","title":"ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIAL OR COMPLETE","url":"https://www.omim.org/entry/613743"},{"mim_id":"610613","title":"CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 1; CYP11B1","url":"https://www.omim.org/entry/610613"},{"mim_id":"610322","title":"TRANSCRIPTIONAL REGULATING FACTOR 1; TRERF1","url":"https://www.omim.org/entry/610322"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":990.8}],"url":"https://www.proteinatlas.org/search/CYP11A1"},"hgnc":{"alias_symbol":["P450SCC"],"prev_symbol":["CYP11A"]},"alphafold":{"accession":"P05108","domains":[{"cath_id":"1.10.630.10","chopping":"47-512","consensus_level":"medium","plddt":97.8653,"start":47,"end":512}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05108","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05108-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05108-F1-predicted_aligned_error_v6.png","plddt_mean":91.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP11A1","jax_strain_url":"https://www.jax.org/strain/search?query=CYP11A1"},"sequence":{"accession":"P05108","fasta_url":"https://rest.uniprot.org/uniprotkb/P05108.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05108/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05108"}},"corpus_meta":[{"pmid":"3011839","id":"PMC_3011839","title":"Hormonal regulation of P450scc (20,22-desmolase) and P450c17 (17 alpha-hydroxylase/17,20-lyase) in cultured human granulosa cells.","date":"1986","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/3011839","citation_count":277,"is_preprint":false},{"pmid":"25448732","id":"PMC_25448732","title":"Novel activities of CYP11A1 and their potential physiological significance.","date":"2014","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25448732","citation_count":252,"is_preprint":false},{"pmid":"19491374","id":"PMC_19491374","title":"Transcriptional regulation of steroidogenic genes: STARD1, CYP11A1 and HSD3B.","date":"2009","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/19491374","citation_count":215,"is_preprint":false},{"pmid":"8247022","id":"PMC_8247022","title":"Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP.","date":"1993","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8247022","citation_count":211,"is_preprint":false},{"pmid":"15511223","id":"PMC_15511223","title":"A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin.","date":"2004","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15511223","citation_count":211,"is_preprint":false},{"pmid":"9147642","id":"PMC_9147642","title":"Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9147642","citation_count":201,"is_preprint":false},{"pmid":"8675607","id":"PMC_8675607","title":"ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin.","date":"1996","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8675607","citation_count":186,"is_preprint":false},{"pmid":"22217822","id":"PMC_22217822","title":"Regulation of cholesterol movement to mitochondrial cytochrome P450scc in steroid hormone synthesis.","date":"1992","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22217822","citation_count":150,"is_preprint":false},{"pmid":"14657394","id":"PMC_14657394","title":"A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1).","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14657394","citation_count":142,"is_preprint":false},{"pmid":"24176765","id":"PMC_24176765","title":"The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions.","date":"2013","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24176765","citation_count":136,"is_preprint":false},{"pmid":"8517924","id":"PMC_8517924","title":"Construction and function of fusion enzymes of the human cytochrome P450scc system.","date":"1993","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8517924","citation_count":133,"is_preprint":false},{"pmid":"7750493","id":"PMC_7750493","title":"Expression of the steroidogenic enzyme P450scc in the central and peripheral nervous systems during rodent embryogenesis.","date":"1995","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7750493","citation_count":128,"is_preprint":false},{"pmid":"12145347","id":"PMC_12145347","title":"Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12145347","citation_count":118,"is_preprint":false},{"pmid":"2154474","id":"PMC_2154474","title":"Characterization of the promoter/regulatory region of the bovine CYP11A (P-450scc) gene. Basal and cAMP-dependent expression.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2154474","citation_count":115,"is_preprint":false},{"pmid":"38870290","id":"PMC_38870290","title":"Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38870290","citation_count":101,"is_preprint":false},{"pmid":"16817851","id":"PMC_16817851","title":"An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2.","date":"2006","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/16817851","citation_count":88,"is_preprint":false},{"pmid":"35205347","id":"PMC_35205347","title":"A Review on CYP11A1, CYP17A1, and CYP19A1 Polymorphism Studies: Candidate Susceptibility Genes for Polycystic Ovary Syndrome (PCOS) and Infertility.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35205347","citation_count":85,"is_preprint":false},{"pmid":"33716049","id":"PMC_33716049","title":"The significance of CYP11A1 expression in skin physiology and pathology.","date":"2021","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33716049","citation_count":80,"is_preprint":false},{"pmid":"12161514","id":"PMC_12161514","title":"Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12161514","citation_count":78,"is_preprint":false},{"pmid":"21677063","id":"PMC_21677063","title":"Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells.","date":"2011","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/21677063","citation_count":78,"is_preprint":false},{"pmid":"21195129","id":"PMC_21195129","title":"Regulation of steroid production: analysis of Cyp11a1 promoter.","date":"2010","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21195129","citation_count":77,"is_preprint":false},{"pmid":"7592707","id":"PMC_7592707","title":"Two Sp1-binding sites mediate cAMP-induced transcription of the bovine CYP11A gene through the protein kinase A signaling pathway.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7592707","citation_count":77,"is_preprint":false},{"pmid":"17065579","id":"PMC_17065579","title":"Expression of aromatase, estrogen receptor alpha and beta, androgen receptor, and cytochrome P-450scc in the human early prepubertal testis.","date":"2006","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/17065579","citation_count":76,"is_preprint":false},{"pmid":"21159840","id":"PMC_21159840","title":"Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia.","date":"2010","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21159840","citation_count":74,"is_preprint":false},{"pmid":"10936034","id":"PMC_10936034","title":"The expression of the sex steroid-synthesizing enzymes CYP11A1, 3beta-HSD, CYP17, and CYP19 in gonads and adrenals of adult and developing zebra finches.","date":"2000","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10936034","citation_count":74,"is_preprint":false},{"pmid":"1333053","id":"PMC_1333053","title":"3',5'-cyclic adenosine monophosphate-dependent transcription of the CYP11A (cholesterol side chain cleavage cytochrome P450) gene involves a DNA response element containing a putative binding site for transcription factor Sp1.","date":"1992","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1333053","citation_count":71,"is_preprint":false},{"pmid":"15126571","id":"PMC_15126571","title":"Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15126571","citation_count":71,"is_preprint":false},{"pmid":"39001720","id":"PMC_39001720","title":"Biological Effects of CYP11A1-Derived Vitamin D and Lumisterol Metabolites in the Skin.","date":"2024","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/39001720","citation_count":69,"is_preprint":false},{"pmid":"15026180","id":"PMC_15026180","title":"Function of Cyp11a1 in animal models.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15026180","citation_count":68,"is_preprint":false},{"pmid":"10383457","id":"PMC_10383457","title":"Role of Sp1 in cAMP-dependent transcriptional regulation of the bovine CYP11A gene.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10383457","citation_count":68,"is_preprint":false},{"pmid":"22201776","id":"PMC_22201776","title":"Gonadal transactivation of STARD1, CYP11A1 and HSD3B.","date":"2012","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/22201776","citation_count":66,"is_preprint":false},{"pmid":"27815210","id":"PMC_27815210","title":"Function of CYP11A1 in the mitochondria.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27815210","citation_count":63,"is_preprint":false},{"pmid":"9794480","id":"PMC_9794480","title":"Induction of Ad4BP/SF-1, steroidogenic acute regulatory protein, and cytochrome P450scc enzyme system expression in newly established human granulosa cell lines.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9794480","citation_count":62,"is_preprint":false},{"pmid":"14637024","id":"PMC_14637024","title":"The F-G loop region of cytochrome P450scc (CYP11A1) interacts with the phospholipid membrane.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/14637024","citation_count":61,"is_preprint":false},{"pmid":"1666853","id":"PMC_1666853","title":"Cytochrome P450 side-chain cleavage (P450scc) in the hen ovary. II. P450scc messenger RNA, immunoreactive protein, and enzyme activity in developing granulosa cells.","date":"1991","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/1666853","citation_count":58,"is_preprint":false},{"pmid":"9231058","id":"PMC_9231058","title":"Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression.","date":"1997","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9231058","citation_count":57,"is_preprint":false},{"pmid":"15635147","id":"PMC_15635147","title":"Ah Receptor-mediated impairment of interrenal steroidogenesis involves StAR protein and P450scc gene attenuation in rainbow trout.","date":"2005","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/15635147","citation_count":56,"is_preprint":false},{"pmid":"7798178","id":"PMC_7798178","title":"Contribution of Ad4BP, a steroidogenic cell-specific transcription factor, to regulation of the human CYP11A and bovine CYP11B genes through their distal promoters.","date":"1994","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7798178","citation_count":55,"is_preprint":false},{"pmid":"12081479","id":"PMC_12081479","title":"Probing the interaction of bovine cytochrome P450scc (CYP11A1) with adrenodoxin: evaluating site-directed mutations by molecular modeling.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12081479","citation_count":54,"is_preprint":false},{"pmid":"9890963","id":"PMC_9890963","title":"An additional electrostatic interaction between adrenodoxin and P450c27 (CYP27A1) results in tighter binding than between adrenodoxin and p450scc (CYP11A1).","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9890963","citation_count":53,"is_preprint":false},{"pmid":"25448743","id":"PMC_25448743","title":"CYP11A1 in skin: an alternative route to photoprotection by vitamin D compounds.","date":"2014","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25448743","citation_count":52,"is_preprint":false},{"pmid":"12617804","id":"PMC_12617804","title":"Expression of zebrafish cyp11a1 as a maternal transcript and in yolk syncytial layer.","date":"2002","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/12617804","citation_count":52,"is_preprint":false},{"pmid":"21273442","id":"PMC_21273442","title":"Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.","date":"2011","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21273442","citation_count":52,"is_preprint":false},{"pmid":"11287037","id":"PMC_11287037","title":"Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism.","date":"2001","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/11287037","citation_count":51,"is_preprint":false},{"pmid":"9578606","id":"PMC_9578606","title":"Expression of catalytically active human cytochrome p450scc in Escherichia coli and mutagenesis of isoleucine-462.","date":"1998","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9578606","citation_count":51,"is_preprint":false},{"pmid":"10583724","id":"PMC_10583724","title":"Sex- and age-specific differences in human brain CYP11A1 mRNA expression.","date":"1999","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10583724","citation_count":49,"is_preprint":false},{"pmid":"8119986","id":"PMC_8119986","title":"Actions of two different cAMP-responsive sequences and an enhancer of the human CYP11A1 (P450scc) gene in adrenal Y1 and placental JEG-3 cells.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8119986","citation_count":47,"is_preprint":false},{"pmid":"15223135","id":"PMC_15223135","title":"Testicular cytochrome P450scc and LHR as possible targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the mouse.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15223135","citation_count":46,"is_preprint":false},{"pmid":"8026494","id":"PMC_8026494","title":"Regulatory mechanisms of cAMP-dependent and cell-specific expression of human steroidogenic cytochrome P450scc (CYP11A1) gene.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8026494","citation_count":44,"is_preprint":false},{"pmid":"17210646","id":"PMC_17210646","title":"Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and c-Jun phosphorylation.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17210646","citation_count":44,"is_preprint":false},{"pmid":"14576461","id":"PMC_14576461","title":"Transcriptional regulation of CYP11A1.","date":"2003","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/14576461","citation_count":43,"is_preprint":false},{"pmid":"18573681","id":"PMC_18573681","title":"Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18573681","citation_count":43,"is_preprint":false},{"pmid":"1863358","id":"PMC_1863358","title":"Expression and regulation of adrenodoxin and P450scc mRNA in rodent tissues.","date":"1991","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1863358","citation_count":43,"is_preprint":false},{"pmid":"17594537","id":"PMC_17594537","title":"Transcriptional regulation of human CYP11A1 in gonads and adrenals.","date":"2007","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/17594537","citation_count":42,"is_preprint":false},{"pmid":"32447000","id":"PMC_32447000","title":"CYP11A1-derived vitamin D3 products protect against UVB-induced inflammation and promote keratinocytes differentiation.","date":"2020","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32447000","citation_count":42,"is_preprint":false},{"pmid":"23555723","id":"PMC_23555723","title":"Abnormal apoptosis of trophoblastic cells is related to the up-regulation of CYP11A gene in placenta of preeclampsia patients.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23555723","citation_count":41,"is_preprint":false},{"pmid":"23337730","id":"PMC_23337730","title":"Varied clinical presentations of seven patients with mutations in CYP11A1 encoding the cholesterol side-chain cleavage enzyme, P450scc.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23337730","citation_count":41,"is_preprint":false},{"pmid":"23966322","id":"PMC_23966322","title":"Misregulated progesterone secretion and impaired pregnancy in Cyp11a1 transgenic mice.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23966322","citation_count":41,"is_preprint":false},{"pmid":"19125849","id":"PMC_19125849","title":"Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period.","date":"2009","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/19125849","citation_count":41,"is_preprint":false},{"pmid":"9029712","id":"PMC_9029712","title":"Transcriptional regulation of the CYP11A1 and ferredoxin genes.","date":"1997","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/9029712","citation_count":40,"is_preprint":false},{"pmid":"23630275","id":"PMC_23630275","title":"Steroidogenic enzyme Cyp11a1 regulates Type 2 CD8+ T cell skewing in allergic lung disease.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23630275","citation_count":39,"is_preprint":false},{"pmid":"22798247","id":"PMC_22798247","title":"Increased expression of P450scc and CYP17 in development of endogenous hyperandrogenism in a rat model of PCOS.","date":"2012","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/22798247","citation_count":39,"is_preprint":false},{"pmid":"11459837","id":"PMC_11459837","title":"The interaction of bovine adrenodoxin with CYP11A1 (cytochrome P450scc) and CYP11B1 (cytochrome P45011beta ). Acceleration of reduction and substrate conversion by site-directed mutagenesis of adrenodoxin.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11459837","citation_count":38,"is_preprint":false},{"pmid":"16844298","id":"PMC_16844298","title":"Vitamin K deficiency reduces testosterone production in the testis through down-regulation of the Cyp11a a cholesterol side chain cleavage enzyme in rats.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16844298","citation_count":38,"is_preprint":false},{"pmid":"25130438","id":"PMC_25130438","title":"Lumisterol is metabolized by CYP11A1: discovery of a new pathway.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25130438","citation_count":37,"is_preprint":false},{"pmid":"38320513","id":"PMC_38320513","title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.","date":"2023","source":"NEJM evidence","url":"https://pubmed.ncbi.nlm.nih.gov/38320513","citation_count":34,"is_preprint":false},{"pmid":"19682541","id":"PMC_19682541","title":"Zebrafish cyp11a1 and hsd3b genes: structure, expression and steroidogenic development during embryogenesis.","date":"2009","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19682541","citation_count":34,"is_preprint":false},{"pmid":"23870673","id":"PMC_23870673","title":"The steroidogenic enzyme Cyp11a1 is essential for development of peanut-induced intestinal anaphylaxis.","date":"2013","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23870673","citation_count":34,"is_preprint":false},{"pmid":"35688208","id":"PMC_35688208","title":"The neurosteroid pregnenolone is synthesized by a mitochondrial P450 enzyme other than CYP11A1 in human glial cells.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35688208","citation_count":34,"is_preprint":false},{"pmid":"1446636","id":"PMC_1446636","title":"Regulation of human cytochrome P450scc and adrenodoxin messenger ribonucleic acids in JEG-3 cytotrophoblast cells.","date":"1992","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1446636","citation_count":33,"is_preprint":false},{"pmid":"19794152","id":"PMC_19794152","title":"DNA methylation is not involved in preovulatory down-regulation of CYP11A1, HSD3B1, and CYP19A1 in bovine follicles but may have a role in permanent silencing of CYP19A1 in large granulosa lutein cells.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19794152","citation_count":33,"is_preprint":false},{"pmid":"18056793","id":"PMC_18056793","title":"Regulation of Kruppel-like factor 4, 9, and 13 genes and the steroidogenic genes LDLR, StAR, and CYP11A in ovarian granulosa cells.","date":"2007","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18056793","citation_count":32,"is_preprint":false},{"pmid":"1666852","id":"PMC_1666852","title":"Cytochrome P450 side-chain cleavage (P450scc) in the hen ovary. I. Regulation of P450scc messenger RNA levels and steroidogenesis in theca cells of developing follicles.","date":"1991","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/1666852","citation_count":32,"is_preprint":false},{"pmid":"16764871","id":"PMC_16764871","title":"A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome.","date":"2006","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/16764871","citation_count":32,"is_preprint":false},{"pmid":"8216855","id":"PMC_8216855","title":"Differential regulation of the CYP11A1 (P450scc) and ferredoxin genes in adrenal and placental cells.","date":"1993","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8216855","citation_count":31,"is_preprint":false},{"pmid":"35775377","id":"PMC_35775377","title":"CYP11A1‑derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas.","date":"2022","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35775377","citation_count":30,"is_preprint":false},{"pmid":"24404170","id":"PMC_24404170","title":"Targeting of GFP-Cre to the mouse Cyp11a1 locus both drives cre recombinase expression in steroidogenic cells and permits generation of Cyp11a1 knock out mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24404170","citation_count":30,"is_preprint":false},{"pmid":"17365614","id":"PMC_17365614","title":"Alteration of brain and interrenal StAR protein, P450scc, and Cyp11beta mRNA levels in atlantic salmon after nominal waterborne exposure to the synthetic pharmaceutical estrogen ethynylestradiol.","date":"2007","source":"Journal of toxicology and environmental health. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17365614","citation_count":30,"is_preprint":false},{"pmid":"10549824","id":"PMC_10549824","title":"Expression of cytochrome P450scc mRNA in the hippocampus of patients with temporal lobe epilepsy.","date":"1999","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10549824","citation_count":30,"is_preprint":false},{"pmid":"22699877","id":"PMC_22699877","title":"Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22699877","citation_count":29,"is_preprint":false},{"pmid":"11020552","id":"PMC_11020552","title":"Localization of p450scc and 5alpha-reductase type-2 in the cerebellum of fetal and newborn sheep.","date":"2000","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11020552","citation_count":29,"is_preprint":false},{"pmid":"8385739","id":"PMC_8385739","title":"Dexamethasone inhibits corticotropin-induced accumulation of CYP11A and CYP17 messenger RNAs in bovine adrenocortical cells.","date":"1993","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8385739","citation_count":28,"is_preprint":false},{"pmid":"15159300","id":"PMC_15159300","title":"Population-based case-control study of CYP11A gene polymorphism and breast cancer risk.","date":"2004","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15159300","citation_count":28,"is_preprint":false},{"pmid":"10556557","id":"PMC_10556557","title":"Conformational dynamics and molecular interaction reactions of recombinant cytochrome p450scc (CYP11A1) detected by fluorescence energy transfer.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10556557","citation_count":27,"is_preprint":false},{"pmid":"30620006","id":"PMC_30620006","title":"Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing.","date":"2018","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/30620006","citation_count":27,"is_preprint":false},{"pmid":"15026086","id":"PMC_15026086","title":"Expression of cytochrome P450scc mRNA and protein in the rat kidney from birth to adulthood.","date":"2004","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15026086","citation_count":26,"is_preprint":false},{"pmid":"8703023","id":"PMC_8703023","title":"Characterization of the upstream sequence of the human CYP11A1 gene for cell type-specific expression.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8703023","citation_count":26,"is_preprint":false},{"pmid":"18001058","id":"PMC_18001058","title":"Steroidogenic acute regulatory (StAR) protein and cholesterol side-chain cleavage (P450scc) as molecular and cellular targets for 17alpha-ethynylestradiol in salmon previtellogenic oocytes.","date":"2007","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/18001058","citation_count":26,"is_preprint":false},{"pmid":"26774298","id":"PMC_26774298","title":"Effects of fluoride and aluminum on expressions of StAR and P450scc of related steroidogenesis in guinea pigs' testis.","date":"2016","source":"Chemosphere","url":"https://pubmed.ncbi.nlm.nih.gov/26774298","citation_count":26,"is_preprint":false},{"pmid":"8394339","id":"PMC_8394339","title":"Regulation of expression of the CYP11A (P450scc) gene in bovine ovarian luteal cells by forskolin and phorbol esters.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8394339","citation_count":25,"is_preprint":false},{"pmid":"15927889","id":"PMC_15927889","title":"Adrenodoxin (Adx) and CYP11A1 (P450scc) induce apoptosis by the generation of reactive oxygen species in mitochondria.","date":"2005","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15927889","citation_count":25,"is_preprint":false},{"pmid":"24793009","id":"PMC_24793009","title":"CYP11A1 microsatellite (tttta)n polymorphism in PCOS women from South India.","date":"2014","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24793009","citation_count":25,"is_preprint":false},{"pmid":"31313246","id":"PMC_31313246","title":"The Footprints of Oxidative Stress and Mitochondrial Impairment in Arsenic Trioxide-Induced Testosterone Release Suppression in Pubertal and Mature F1-Male Balb/c Mice via the Downregulation of 3β-HSD, 17β-HSD, and CYP11a Expression.","date":"2019","source":"Biological trace element research","url":"https://pubmed.ncbi.nlm.nih.gov/31313246","citation_count":24,"is_preprint":false},{"pmid":"37315842","id":"PMC_37315842","title":"Retinoic acid enhances ovarian steroidogenesis by regulating granulosa cell proliferation and MESP2/STAR/CYP11A1 pathway.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/37315842","citation_count":23,"is_preprint":false},{"pmid":"30299480","id":"PMC_30299480","title":"Characterization of the CYP11A1 Nonsynonymous Variant p.E314K in Children Presenting With Adrenal Insufficiency.","date":"2019","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30299480","citation_count":23,"is_preprint":false},{"pmid":"33107570","id":"PMC_33107570","title":"Antifibrogenic Activities of CYP11A1-derived Vitamin D3-hydroxyderivatives Are Dependent on RORγ.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33107570","citation_count":23,"is_preprint":false},{"pmid":"26332453","id":"PMC_26332453","title":"DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.","date":"2015","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/26332453","citation_count":23,"is_preprint":false},{"pmid":"34015388","id":"PMC_34015388","title":"Neurosteroidogenic enzymes: CYP11A1 in the central nervous system.","date":"2021","source":"Frontiers in neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34015388","citation_count":22,"is_preprint":false},{"pmid":"36432468","id":"PMC_36432468","title":"Novel CYP11A1-Derived Vitamin D and Lumisterol Biometabolites for the Management of COVID-19.","date":"2022","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36432468","citation_count":22,"is_preprint":false},{"pmid":"27502676","id":"PMC_27502676","title":"Atomic Force Microscopy Study of Protein-Protein Interactions in the Cytochrome CYP11A1 (P450scc)-Containing Steroid Hydroxylase System.","date":"2010","source":"Nanoscale research letters","url":"https://pubmed.ncbi.nlm.nih.gov/27502676","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54659,"output_tokens":9738,"usd":0.155024,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20127,"output_tokens":4628,"usd":0.108167,"stage2_stop_reason":"end_turn"},"total_usd":0.263191,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"P450scc (CYP11A1) is the single enzyme mediating conversion of cholesterol to pregnenolone (20,22-desmolase activity) in human steroidogenesis; its mRNA accumulation in granulosa cells is stimulated in a dose-dependent, cAMP-mediated manner by hCG and FSH, indicating gonadotropin-specific transcriptional regulation.\",\n      \"method\": \"Northern blot hybridization with 32P-labeled P450scc cDNA; progesterone secretion assay; hormone dose-response in primary human granulosa cell cultures\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct mRNA quantification plus functional secretion assay, multiple hormonal conditions, replicated across labs in subsequent work\",\n      \"pmids\": [\"3011839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The bovine CYP11A1 promoter contains a cAMP-responsive region between -186 and -101 bp that functions independently of canonical CRE sequences; sequences between -183 and -83 bp drive both basal and cAMP-enhanced transcription when fused to a heterologous promoter in adrenocortical cells.\",\n      \"method\": \"Deletion mutagenesis of the 5'-flanking region linked to a reporter gene; transient transfection into mouse Y1 adrenal tumor cells and primary bovine adrenocortical cells; primer extension for transcription start site mapping\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic deletion mutagenesis with reporter gene in two steroidogenic cell systems\",\n      \"pmids\": [\"2154474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"A G-rich sequence element at -118 to -100 bp in the bovine CYP11A promoter binds an Sp1-related protein and overlaps with a putative adrenal-specific protein binding site; deletion of this minimal cAMP-responsive sequence abolishes cAMP-dependent reporter gene transcription in Y1 cells.\",\n      \"method\": \"DNase I footprinting, electrophoretic mobility shift assay (EMSA), competition analysis, reporter gene transfection into Y1 adrenocortical cells\",\n      \"journal\": \"Molecular Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA with competition plus functional reporter assays, minimal sequence mapped\",\n      \"pmids\": [\"1333053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Transfer of cholesterol to the inner mitochondrial membrane–bound CYP11A1 is the rate-limiting step in steroid synthesis; cholesterol supply involves cytoskeletal elements and sterol carrier protein-2 (SCP2) for outer membrane delivery, and steroidogenesis activator peptide plus GTP facilitate inner-to-outer membrane cholesterol transfer.\",\n      \"method\": \"Cell fractionation, inhibitor studies, reconstitution of mitochondrial cholesterol transfer with defined factors, digitonin solubilization of outer mitochondrial membranes\",\n      \"journal\": \"The Journal of Steroid Biochemistry and Molecular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical approaches in the same review/study, but partly a review compiling earlier work\",\n      \"pmids\": [\"22217822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"cAMP-dependent regulation of CYP11A1 mRNA in JEG-3 cytotrophoblast cells is principally transcriptional (as shown by RNA polymerase run-on assays), whereas adrenodoxin mRNA regulation is posttranscriptional and not mediated by the AUUUA sequences in its 3'-UTR.\",\n      \"method\": \"Chimeric vector transfection with swapped 3'-UTRs; RNA polymerase run-on assay; actinomycin-D mRNA stability assay; cycloheximide treatment\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — run-on assay directly demonstrated transcriptional regulation; multiple orthogonal methods (chimeric constructs, stability assay, transcription run-on)\",\n      \"pmids\": [\"1446636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The steroidogenic cell-specific transcription factor Ad4BP (SF-1) activates the CYP11A1 (CYP11A) gene through an Ad4 cis-element in both adrenal and Leydig cells; activation is potentiated by the cAMP pathway via protein kinase A and is absent in nonsteroidogenic cells lacking Ad4BP.\",\n      \"method\": \"Reporter gene constructs with combinations of Ad1/Ad4 cis-elements; transient transfection into Y1, I-10, and PC-12 cells; cotransfection of Ad4BP expression vector; immunoblot for Ad4BP\",\n      \"journal\": \"Molecular Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic promoter element analysis plus gain-of-function with Ad4BP expression vector, multiple cell types\",\n      \"pmids\": [\"8247022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CYP11A1 fusion proteins with adrenodoxin reductase and adrenodoxin (P450scc-AdRed-Adx triple fusion) achieve substantially higher pregnenolone production than triple transfection of individual components, demonstrating that physical linkage of the Type I electron transfer chain components enhances catalytic efficiency.\",\n      \"method\": \"Construction of fusion protein expression vectors by PCR/cassette assembly; transfection into COS-1 cells; pregnenolone secretion assay using 22R-hydroxycholesterol substrate\",\n      \"journal\": \"DNA and Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct enzymatic activity assay with engineered fusion proteins and comparison to wild-type triple transfection\",\n      \"pmids\": [\"8517924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human CYP11A1 gene contains a proximal cAMP-responsive sequence (P-CRS) active in both adrenal Y1 and placental JEG-3 cells, and an upstream CRS (U-CRS, -1621 to -1503) plus an enhancer (-1931 to -1822) that function only in Y1 cells; U-CRS-mediated cAMP response requires protein kinase A, whereas P-CRS does not.\",\n      \"method\": \"Deletion analysis with reporter gene constructs; transient transfection into Y1 and JEG-3 cells; protein kinase A-deficient cell line; DNase I footprinting; gel mobility shift and antibody supershift\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic deletion mutagenesis, PKA-deficient cells, and DNA-protein interaction assays\",\n      \"pmids\": [\"8119986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CREB/ATF proteins and Ad4BP (SF-1) bind to closely arranged CRE-like and Ad4 sequences in the upstream CYP11A1 regulatory region and act synergistically to confer cAMP-responsive, steroidogenic cell-specific expression.\",\n      \"method\": \"DNase I footprinting with bovine adrenal nuclear extracts; point mutation analysis; reporter gene transfection\",\n      \"journal\": \"European Journal of Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — footprinting plus point mutagenesis with functional reporter assays\",\n      \"pmids\": [\"8026494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"An upstream element (AdE) in the human CYP11A1 gene containing two protein binding regions (AdE1 and AdE2) that bind NF1- and Sp1-like proteins enhances CYP11A1 expression specifically in steroidogenic cells; AdE1 and AdE2 act combinatorially for full activity.\",\n      \"method\": \"EMSA, footprinting, competition, antibody supershift; mutagenesis of binding sites; reporter gene transfection into steroidogenic and nonsteroidogenic cell lines\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal DNA-protein interaction methods plus functional transfection data\",\n      \"pmids\": [\"8703023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Two Sp1-binding sites at -111/-100 bp and -70/-50 bp in the bovine CYP11A promoter are necessary for both basal and cAMP-dependent transcription; mutations eliminating Sp1 binding at -111/-100 markedly reduce cAMP-induced transcription via the protein kinase A pathway.\",\n      \"method\": \"EMSA with purified Sp1; anti-Sp1 antibody supershift; mutation analysis; reporter gene transfection into Y1 adrenal cells\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — purified Sp1 binding confirmed, mutation-function correlation established in adrenal cells\",\n      \"pmids\": [\"7592707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human CYP11A1 expressed in E. coli retains catalytic activity comparable to placenta-purified enzyme; mutation of Ile-462 to Leu decreases kcat with cholesterol and increases Km for 22R-hydroxycholesterol but not for 20α-hydroxycholesterol, indicating that Ile-462 resides near the side-chain binding site.\",\n      \"method\": \"Recombinant expression in E. coli; enzyme purification; kinetic assays (Km, Vmax, kcat) with cholesterol and hydroxycholesterol substrates; site-directed mutagenesis\",\n      \"journal\": \"Archives of Biochemistry and Biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic characterization plus mutagenesis with substrate specificity readout\",\n      \"pmids\": [\"9578606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Sp1 alone is sufficient to confer cAMP-dependent transcriptional activation of CYP11A1 through the -118/-100 element; Sp3 does not repress Sp1-dependent activation at this promoter, unlike other GC-rich promoters.\",\n      \"method\": \"Drosophila SL2 cells lacking endogenous Sp factors; cotransfection of Sp1, Sp3, Sp4 expression vectors with CYP11A reporter; cotransfection of PKA catalytic subunit; mutation of -118/-100 element\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — use of Sp-negative SL2 cells with reconstitution is a clean gain-of-function approach\",\n      \"pmids\": [\"10383457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Positively charged residues K403, K405, and R426 on the proximal surface of bovine P450scc (CYP11A1) are required for electrostatic interaction with adrenodoxin; R426Q mutation completely abolishes adrenodoxin binding while retaining CO-binding and chemical reducibility.\",\n      \"method\": \"Site-directed mutagenesis of 13 P450scc variants; adrenodoxin binding assay; reduction kinetics; enzymatic activity measurement; molecular modeling and docking\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of multiple residues with functional characterization (binding, reduction, activity) plus structural modeling\",\n      \"pmids\": [\"12081479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Adrenodoxin mutants with C-terminal truncation and introduction of a tryptophan residue (S112W) form more stable complexes with CYP11A1, show faster reduction rates, and achieve ~100-fold increased efficiency in cholesterol-to-pregnenolone conversion, demonstrating that adrenodoxin–CYP11A1 complex stability directly determines catalytic throughput.\",\n      \"method\": \"Site-directed mutagenesis of adrenodoxin; kinetic measurement of CYP11A1·CO complex formation; cholesterol conversion assay\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinetics with multiple mutants and quantitative activity measurement\",\n      \"pmids\": [\"11459837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cyp11a1 null mice completely lack steroid synthesis, die shortly after birth (rescued by steroid injection), develop ectopic Cyp21 expression in the testis due to absence of glucocorticoid feedback, and exhibit feminization of XY males—establishing CYP11A1 as essential for the first and obligatory step of all steroid hormone biosynthesis.\",\n      \"method\": \"Targeted gene disruption (neo insertion into exon 1); steroid measurements; hormonal rescue experiments; histological analysis of adrenals/gonads; RT-PCR for ectopic gene expression\",\n      \"journal\": \"Molecular Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete KO with multiple phenotypic readouts, hormonal rescue, and ectopic gene expression analysis\",\n      \"pmids\": [\"12145347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A compound heterozygous CYP11A1 mutation (R353W + A189V/splicing) causes partial P450scc deficiency in humans; R353W markedly reduces enzymatic activity, demonstrating that Arg353 is a crucial residue for catalytic function.\",\n      \"method\": \"Sequencing of CYP11A1; site-directed mutagenesis to recreate mutations in F2 fusion protein; pregnenolone production assay in transfected COS-1 cells\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional enzyme assay directly linked to patient phenotype\",\n      \"pmids\": [\"12161514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Purified CYP11A1 (P450scc) reconstituted with adrenodoxin and adrenodoxin reductase hydroxylates vitamin D3 to produce 20-hydroxyvitamin D3 and 20,22-dihydroxyvitamin D3 as major products, and converts 7-dehydrocholesterol to 7-dehydropregnenolone—identifying a vitamin D hydroxylation pathway distinct from classical 1α/25-hydroxylation.\",\n      \"method\": \"In vitro reconstituted system with purified CYP11A1, adrenodoxin, adrenodoxin reductase; NADPH-dependent metabolism assay; product identification by MS and comparison with standards\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — fully reconstituted in vitro system with purified components, product identification by MS; replicated in subsequent studies\",\n      \"pmids\": [\"14657394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The F-G loop region (residues V212 and L219) of CYP11A1 becomes localized to a hydrophobic environment upon membrane binding, as shown by fluorescent probe blue-shift, indicating that CYP11A1 has a monotopic association with the phospholipid membrane mediated at least in part through the F-G loop.\",\n      \"method\": \"Hydrophobicity profiling; A'-helix deletion mutagenesis; cysteine-scanning mutagenesis (L24C, V212C, L219C) with NBD fluorescent labeling; fluorescence blue-shift assay with phospholipid vesicles; tryptophan quenching by acrylamide\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis combined with fluorescence spectroscopy in membrane-binding assay, multiple residues tested\",\n      \"pmids\": [\"14637024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"P450scc enzyme and its electron transfer partners (adrenodoxin, adrenodoxin reductase, MLN64) are expressed and functionally active in skin mitochondria; purified P450scc and placental/adrenal mitochondria convert 7-dehydrocholesterol to 7-dehydropregnenolone with kinetics similar to cholesterol conversion.\",\n      \"method\": \"RT-PCR and immunoblot for P450scc system components in skin cells; functional assay of 7-DHC conversion in isolated skin mitochondria; product identity confirmed by NMR, MS, and comparison with synthetic standard\",\n      \"journal\": \"European Journal of Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity demonstrated in isolated organelles; product identity confirmed by multiple analytical methods\",\n      \"pmids\": [\"15511223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CYP11A1 metabolizes vitamin D2 in a reconstituted system to produce 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2; adrenal mitochondria also metabolize vitamin D2 with this pathway inhibited by the CYP11A1 inhibitor aminoglutethimide, confirming CYP11A1 as responsible.\",\n      \"method\": \"Reconstituted P450scc system; NMR structure determination of products; adrenal mitochondria metabolism with pharmacological inhibitor control; keratinocyte DNA synthesis assay\",\n      \"journal\": \"The FEBS Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted system with NMR product identification plus mitochondrial inhibition control\",\n      \"pmids\": [\"16817851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HIPK3 and c-Jun are required for basal and cAMP-stimulated CYP11A1 expression; cAMP stimulation leads to HIPK3-mediated phosphorylation of JNK and c-Jun, and these phosphorylation events enhance SF-1 transcriptional activity for CYP11A1.\",\n      \"method\": \"Cotransfection/overexpression of HIPK3 and c-Jun; siRNA knockdown; luciferase reporter assay; phosphorylation detection; SF-1 activity assays in adrenal/gonadal cells\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and loss-of-function with defined phosphorylation readout and reporter gene assay\",\n      \"pmids\": [\"17210646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CYP11A1 hydroxylates vitamin D3 sequentially in phospholipid vesicles producing 20(OH)D3 then 20,23(OH)2D3 then 17,20,23(OH)3D3; the Km for vitamin D3 in vesicles is 3.3 mol/mol phospholipid, with StAR protein stimulating vitamin D3 exchange between vesicles.\",\n      \"method\": \"Reconstituted membrane-bound P450scc kinetics; gel filtration of vesicles; sequential product identification; N-62 StAR protein addition assay\",\n      \"journal\": \"The International Journal of Biochemistry & Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — detailed kinetic characterization with reconstituted membrane system and StAR protein\",\n      \"pmids\": [\"18573681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mutation of the proximal SF-1-binding site in the Cyp11a1 promoter in vivo causes downregulation of CYP11A1 in the adrenal and testis but not in the ovary and placenta, resulting in attenuated corticosterone circadian rhythms and blunted stress response.\",\n      \"method\": \"Transgenic mouse with mutated SF-1-binding site driving reporter gene; endogenous gene expression analysis; corticosterone measurements under stress\",\n      \"journal\": \"Molecular and Cellular Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic/knock-in mutation with tissue-specific and physiological phenotype readouts\",\n      \"pmids\": [\"21195129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A novel CYP11A1 missense mutation A269V retains 11% of wild-type P450scc activity and causes nonclassic lipoid congenital adrenal hyperplasia when compound heterozygous with a frameshift mutation, establishing a direct genotype-activity-phenotype relationship.\",\n      \"method\": \"Sequencing; site-directed mutagenesis recreating mutations in F2 fusion protein; pregnenolone production assay (Vmax/Km) in transfected COS-1 cells\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative in vitro enzyme assay with mutagenesis directly linked to clinical phenotype\",\n      \"pmids\": [\"21159840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CYP11A1 produces 22-hydroxyvitamin D3 and 20,22-dihydroxyvitamin D3 as additional products of vitamin D3 metabolism; these 22-hydroxy derivatives are biologically active on keratinocytes via the vitamin D receptor (VDR), stimulating VDR translocation to the nucleus and inhibiting proliferation.\",\n      \"method\": \"Reconstituted P450scc reaction; NMR structure determination; purified 22(OH)D3 as substrate for further P450scc action; keratinocyte proliferation/differentiation assays; VDR translocation immunofluorescence\",\n      \"journal\": \"Drug Metabolism and Disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted enzymatic system with NMR, plus cellular VDR activity assays; builds on replicated prior work\",\n      \"pmids\": [\"21677063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CYP11A1 overexpression in trophoblastic cells reduces proliferation and induces apoptosis via activation of caspase-3; in preeclampsia placenta, CYP11A1 is significantly upregulated at both mRNA and protein levels.\",\n      \"method\": \"CYP11A1 overexpression in HTR8/SVneo trophoblastic cells; TUNEL staining for apoptosis; caspase-3 activation assay; RT-PCR and Western blot in patient tissue\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression with defined apoptosis readout but single method for cellular mechanism\",\n      \"pmids\": [\"23555723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cyp11a1 enzymatic activity in CD8+ T cells is required for IL-4-induced conversion from IFN-γ to IL-13 production; inhibition with aminoglutethimide or shRNA knockdown prevents this phenotypic conversion without affecting T-bet or GATA3 expression.\",\n      \"method\": \"Aminoglutethimide pharmacological inhibition; shRNA knockdown of Cyp11a1; cytokine measurement by ELISA/RT-PCR; adoptive transfer into CD8-deficient recipients; airway hyperresponsiveness measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function by two orthogonal methods (inhibitor + shRNA) with in vivo adoptive transfer confirmation\",\n      \"pmids\": [\"23630275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cyp11a1 inhibition (aminoglutethimide) prevents peanut-induced allergic diarrhea and intestinal inflammation; shRNA silencing in polarized TH2 CD4+ T cells reduces pregnenolone and IL-13, establishing that Cyp11a1 steroidogenic activity is required for TH2 cytokine production.\",\n      \"method\": \"In vivo aminoglutethimide treatment in peanut sensitization/challenge model; shRNA silencing in polarized T cells; pregnenolone ELISA; IL-13/IL-17A mRNA and protein quantification\",\n      \"journal\": \"The Journal of Allergy and Clinical Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two orthogonal loss-of-function methods (pharmacological + shRNA), in vivo and in vitro confirmation\",\n      \"pmids\": [\"23870673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Overexpression of Cyp11a1 in transgenic mice disrupts normal corpus luteum development, causes progesterone insufficiency during early pregnancy (delayed steroidogenic gene activation, elongated mitochondria, lipid accumulation), and leads to impaired implantation, anomalous placentation, and delayed parturition.\",\n      \"method\": \"BAC transgenic mice with extra Cyp11a1 copies; progesterone ELISA; luteal cell morphology (mitochondrial imaging); gene expression analysis; P4 supplementation rescue\",\n      \"journal\": \"Biology of Reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in vivo model with hormonal, morphological, and developmental phenotype readouts plus rescue experiment\",\n      \"pmids\": [\"23966322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Seven CYP11A1 missense mutations causing P450scc deficiency were characterized; mutations including Phe215Ser retain only 2.5% and Val415Glu/c.835delA lack detectable enzymatic activity, while Ala269Val retains 12%—directly correlating residue identity with catalytic competence.\",\n      \"method\": \"CYP11A1 sequencing; site-directed mutagenesis recreating mutations in F2 fusion protein; pregnenolone production assay in transfected COS-1 cells with apparent kinetic parameters\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative enzyme assay for multiple mutants with kinetic parameters\",\n      \"pmids\": [\"23337730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CYP11A1 metabolizes lumisterol 3 (L3) to produce 24-hydroxy-L3, 22-hydroxy-L3, and 20,22-dihydroxy-L3 as major products, plus pregnalumisterol from side-chain cleavage; this metabolism was confirmed in pig adrenal fragments by LC/MS, establishing a new CYP11A1 substrate pathway.\",\n      \"method\": \"Reconstituted bovine and human CYP11A1 incubation with L3; NMR structure determination of products; pig adrenal fragment assay; LC/MS product detection\",\n      \"journal\": \"The International Journal of Biochemistry & Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted system with purified human and bovine enzyme, NMR confirmation, and tissue validation\",\n      \"pmids\": [\"25130438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Artemisinins directly target LONP1, enhance the LONP1–CYP11A1 physical interaction, and facilitate LONP1-catalyzed proteolytic degradation of CYP11A1 protein, thereby reducing androgen biosynthesis; LONP1 overexpression alone replicates the androgen-lowering effect.\",\n      \"method\": \"Target identification of artemisinins binding LONP1; co-immunoprecipitation of LONP1-CYP11A1 complex; CYP11A1 protein degradation assay; LONP1 overexpression; androgen measurements in rodent PCOS models and human patients\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, gain-of-function with LONP1 overexpression, pharmacological validation in vivo and clinical study\",\n      \"pmids\": [\"38870290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CYP11A1 in steroidogenic cell mitochondria affects mitochondrial morphology; steroidogenic cells exhibit tubular-vesicular cristae (distinct from lamellar cristae in non-steroidogenic cells), and the presence of steroidogenic enzymes in the inner mitochondrial membrane is linked to this morphological feature and degree of cell differentiation.\",\n      \"method\": \"Electron microscopy of steroidogenic vs. non-steroidogenic mitochondria; correlation with Cyp11a1 transgenic mouse studies showing elongated mitochondria upon overexpression\",\n      \"journal\": \"Molecular and Cellular Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — morphological observations corroborated by transgenic overexpression data, but no direct mechanistic experiment linking CYP11A1 activity to cristae shape\",\n      \"pmids\": [\"27815210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The common CYP11A1 variant p.E314K (rs6161, predicted benign) causes missplicing, produces a nonfunctional protein in mammalian cells, and is a major cause of primary adrenal insufficiency when compound heterozygous with other CYP11A1 variants.\",\n      \"method\": \"Next-generation sequencing; in silico splicing prediction; in vitro minigene splicing assay; E. coli enzyme activity assay (showed no loss-of-function); mammalian cell transfection to demonstrate nonfunctional protein; cycloheximide chase not mentioned but splicing assay central\",\n      \"journal\": \"Journal of the Endocrine Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro splicing assay combined with mammalian cell functional study demonstrating nonfunctional protein, orthogonal to E. coli assay\",\n      \"pmids\": [\"30620006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CYP11A1 variant p.E314K causes ~50% decreased protein half-life (increased turnover by cycloheximide chase assay) and retains 60% of wild-type enzymatic activity, establishing that this variant causes primary adrenal insufficiency primarily through impaired protein stability rather than catalytic loss.\",\n      \"method\": \"HEK293T transfection; cycloheximide chase assay for protein stability; pregnenolone production assay from p.E314K-F2 fusion protein in COS-1 cells\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protein stability and enzymatic activity measured by orthogonal in vitro methods\",\n      \"pmids\": [\"30299480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Human glial cells produce pregnenolone via a mitochondrial CYP450 enzyme other than CYP11A1; pregnenolone synthesis in glial cells is not inhibited by CYP11A1 inhibitors (aminoglutethimide, ketoconazole) and is not altered by overexpression of CYP11A1 isoform b, but is inhibited by ferredoxin reductase knockdown—indicating a different mitochondrial P450.\",\n      \"method\": \"Mass spectrometry and ELISA for pregnenolone; pharmacological inhibition (aminoglutethimide, ketoconazole); CYP11A1 isoform b overexpression; siRNA knockdown of NADPH-cytochrome P450 reductase and ferredoxin reductase; ROS modulation\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — negative result for CYP11A1 established by multiple orthogonal approaches (inhibitors, overexpression, siRNA), pointing to alternative enzyme\",\n      \"pmids\": [\"35688208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Antiproliferative and antifibrotic activities of CYP11A1-derived vitamin D3 hydroxyderivatives (20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3) in skin fibroblasts are dependent on functional RORγ; these effects are reversed or abolished in RORγ knockout fibroblasts.\",\n      \"method\": \"Wild-type, heterozygous, and RORγ knockout murine fibroblasts; proliferation assay; TGF-β1-induced collagen synthesis assay; RNA-seq transcriptome analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function (KO) with dose-response assays and transcriptomic validation across three genotypes\",\n      \"pmids\": [\"33107570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ODM-208, a novel CYP11A1 inhibitor, potently suppresses steroid hormone biosynthesis (testosterone to undetectable levels in 87% of patients within one week) in metastatic castration-resistant prostate cancer patients, confirming that CYP11A1 catalytic activity is the primary source of residual androgen biosynthesis in this disease setting.\",\n      \"method\": \"Phase 1/2 clinical trial; pharmacodynamic measurement of circulating testosterone and other steroids; PSA response measurement; adrenal insufficiency as on-target toxicity\",\n      \"journal\": \"NEJM Evidence\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — prospective clinical pharmacodynamics in 92 patients with target-defined hormone suppression\",\n      \"pmids\": [\"38320513\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP11A1 (P450scc) is a mitochondrial inner-membrane cytochrome P450 that receives electrons from NADPH via adrenodoxin reductase and adrenodoxin—interacting through electrostatic contacts at residues K403, K405, and R426—to catalyze the rate-limiting, three-step conversion of cholesterol to pregnenolone (the obligatory first step of all steroidogenesis), and additionally hydroxylates alternative sterol substrates including 7-dehydrocholesterol, vitamin D3/D2, and lumisterol to bioactive metabolites; its transcription in steroidogenic tissues is driven by the cAMP–PKA pathway through SF-1, Sp1, HIPK3/JNK/c-Jun, and tissue-specific enhancer elements, while its protein stability and activity are regulated post-translationally by LONP1-mediated proteolysis, and its enzymatic activity in immune cells (CD8+ T cells, TH2 cells) and skin is required for context-specific steroidogenic and immunomodulatory functions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP11A1 (P450scc) catalyzes the rate-limiting, obligatory first step of all steroid hormone biosynthesis—the side-chain cleavage of cholesterol to pregnenolone—and Cyp11a1-null mice completely lack steroidogenesis, die shortly after birth unless rescued by steroid injection, and show feminization of XY males, establishing the enzyme as indispensable [#0, #15]. The enzyme is membrane-associated, contacting the phospholipid bilayer in part through its F-G loop [#18], and depends on a Type I electron-transfer chain in which adrenodoxin reductase and adrenodoxin deliver NADPH-derived electrons; CYP11A1 engages adrenodoxin through positively charged proximal-surface residues (K403, K405, R426), and the stability of the adrenodoxin·CYP11A1 complex directly sets catalytic throughput [#13, #14]. Cholesterol delivery to the inner-membrane enzyme is itself rate-limiting and requires sterol transfer machinery and StAR-type proteins [#3, #22]. Beyond cholesterol, reconstituted CYP11A1 hydroxylates alternative sterol substrates—7-dehydrocholesterol, vitamin D3, vitamin D2, and lumisterol—generating bioactive metabolites such as 20-hydroxyvitamin D3, whose antiproliferative and antifibrotic effects act through nuclear receptors VDR and RORγ [#17, #19, #20, #25, #31, #37]. Transcription in steroidogenic tissues is driven by cAMP–PKA signaling through SF-1/Ad4BP acting combinatorially with CREB/ATF, Sp1, and NF1-like factors at promoter and upstream enhancer elements, with the HIPK3/JNK/c-Jun module potentiating SF-1 activity [#5, #8, #10, #12, #21]. Post-translationally, CYP11A1 abundance is controlled by LONP1-mediated proteolysis, a mechanism exploited pharmacologically by artemisinins to lower androgen output [#32]. Loss-of-function CYP11A1 mutations cause classic and nonclassic lipoid congenital adrenal hyperplasia and primary adrenal insufficiency, with genotype severity tracking residual catalytic activity or protein stability [#16, #24, #30, #34]. The enzyme also exerts non-adrenal functions: its steroidogenic activity in CD8+ and TH2 cells is required for IL-13/TH2 cytokine production [#27, #28], and pharmacological inhibition (ODM-208) confirms CYP11A1 as the source of residual androgens in castration-resistant prostate cancer [#38].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Established that a single enzyme, P450scc, performs cholesterol-to-pregnenolone conversion in human steroidogenesis and that its expression is hormonally controlled, defining the entry point of steroid synthesis.\",\n      \"evidence\": \"Northern blot and progesterone secretion assays with hCG/FSH dose-response in primary human granulosa cells\",\n      \"pmids\": [\"3011839\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the cis-elements or transcription factors mediating cAMP induction\", \"No structural basis for catalysis addressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Resolved how cholesterol reaches the inner-membrane enzyme, showing that substrate delivery rather than catalysis is the kinetically limiting event in steroidogenesis.\",\n      \"evidence\": \"Cell fractionation, inhibitor studies, and reconstitution of mitochondrial cholesterol transfer with defined factors\",\n      \"pmids\": [\"22217822\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Partly a review compiling earlier work\", \"Relative contributions of SCP2, StAR-type peptides, and GTP not fully quantified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapped the cAMP-responsive transcriptional architecture, identifying SF-1/Ad4BP acting with CREB/ATF, Sp1, and NF1-like factors at distinct proximal and upstream elements to confer cell-specific, hormone-inducible CYP11A1 expression.\",\n      \"evidence\": \"Promoter deletion, footprinting, EMSA/supershift, and reporter transfection across adrenal (Y1), placental (JEG-3), and Sp-negative SL2 cells, plus PKA-deficient lines\",\n      \"pmids\": [\"2154474\", \"1333053\", \"1446636\", \"8247022\", \"8119986\", \"8026494\", \"8703023\", \"7592707\", \"10383457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific differences (e.g. placental vs adrenal use of distinct elements) only partially explained\", \"In vivo relevance of individual elements not yet tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the molecular basis of the redox partnership, showing that specific proximal-surface basic residues mediate electrostatic docking of adrenodoxin and that complex stability dictates catalytic efficiency.\",\n      \"evidence\": \"Site-directed mutagenesis (K403/K405/R426; adrenodoxin S112W), binding/reduction kinetics, cholesterol conversion assays, and molecular docking\",\n      \"pmids\": [\"12081479\", \"11459837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution co-structure of the human complex in the timeline\", \"Dynamics of electron transfer during the three sequential oxidations not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated genetically that CYP11A1 is essential and obligatory for all steroidogenesis, and linked human mutations to P450scc-deficiency phenotypes.\",\n      \"evidence\": \"Cyp11a1 knockout mice with steroid rescue, plus patient mutation analysis recreated in fusion-protein enzyme assays\",\n      \"pmids\": [\"12145347\", \"12161514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish full genotype-phenotype spectrum for partial-activity alleles\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed that CYP11A1 has a broader substrate range than cholesterol, hydroxylating 7-dehydrocholesterol and vitamin D to novel bioactive metabolites, and clarified its monotopic membrane association.\",\n      \"evidence\": \"Reconstituted purified-enzyme systems with MS/NMR product identification, plus fluorescent membrane-binding probes on F-G loop residues\",\n      \"pmids\": [\"14657394\", \"14637024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological abundance and in vivo roles of these metabolites not established at this stage\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended the alternative-substrate catalogue and characterized sequential hydroxylation kinetics in membranes, identifying vitamin D2 and lumisterol products and StAR-stimulated substrate exchange.\",\n      \"evidence\": \"Reconstituted membrane-bound kinetics, NMR/LC-MS product identification, tissue (adrenal, pig adrenal, skin mitochondria) validation\",\n      \"pmids\": [\"15511223\", \"16817851\", \"18573681\", \"25130438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative in vivo contribution of CYP11A1 to circulating vitamin D/lumisterol metabolites not measured\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected CYP11A1-derived sterol metabolites to downstream signaling, showing the hydroxyvitamin D products are biologically active through VDR and RORγ.\",\n      \"evidence\": \"Reconstituted enzymatic production with NMR, keratinocyte/fibroblast proliferation and differentiation assays, VDR translocation imaging, and RORγ knockout fibroblasts\",\n      \"pmids\": [\"21677063\", \"33107570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor selectivity among multiple metabolites not fully dissected\", \"In vivo significance in human skin physiology not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified non-adrenal immune functions, establishing that CYP11A1 steroidogenic activity in CD8+ and TH2 cells is required for IL-13/TH2 cytokine production and allergic inflammation.\",\n      \"evidence\": \"Pharmacological inhibition (aminoglutethimide) plus shRNA knockdown, cytokine quantification, adoptive transfer, and in vivo allergy models\",\n      \"pmids\": [\"23630275\", \"23870673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the active steroid metabolite mediating cytokine switching beyond pregnenolone not pinpointed\", \"Mechanism linking steroid output to cytokine gene regulation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Refined the human disease genotype-activity-phenotype relationship and revealed dosage-sensitive reproductive consequences of CYP11A1 levels.\",\n      \"evidence\": \"Multiple patient missense mutations recreated in fusion-protein enzyme assays with kinetic parameters, plus BAC-transgenic Cyp11a1-overexpressing mice\",\n      \"pmids\": [\"21159840\", \"23337730\", \"23966322\", \"23555723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trophoblast apoptosis mechanism relied on single-method overexpression readout\", \"Causal vs correlative role of CYP11A1 upregulation in preeclampsia not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established that disease can arise through protein-stability defects, not only catalytic loss, exemplified by the missplicing/turnover phenotype of the common p.E314K variant.\",\n      \"evidence\": \"Minigene splicing assay, mammalian-cell expression, cycloheximide-chase half-life measurement, and fusion-protein activity assays\",\n      \"pmids\": [\"30620006\", \"30299480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular machinery degrading the destabilized variant not identified at this stage\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a post-translational control axis, showing LONP1-mediated proteolysis sets CYP11A1 abundance and that artemisinins exploit this to lower androgen biosynthesis.\",\n      \"evidence\": \"Target identification of artemisinins, reciprocal LONP1-CYP11A1 co-IP, degradation assays, LONP1 overexpression, and androgen measurements in PCOS models and patients\",\n      \"pmids\": [\"38870290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LONP1 degradation is regulated physiologically to tune steroidogenesis not established\", \"Structural basis of LONP1 recognition of CYP11A1 unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Validated CYP11A1 as a therapeutic target, with the inhibitor ODM-208 abolishing residual androgen biosynthesis in castration-resistant prostate cancer.\",\n      \"evidence\": \"Phase 1/2 clinical trial with pharmacodynamic steroid measurements and PSA response in 92 patients\",\n      \"pmids\": [\"38320513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"On-target adrenal insufficiency requires steroid replacement\", \"Durability of response and resistance mechanisms not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved which steroid metabolite mediates CYP11A1's immunomodulatory and tissue-specific functions and how its substrate selection between cholesterol and alternative sterols is regulated in vivo.\",\n      \"evidence\": \"No timeline discovery resolves the downstream effector metabolite or in vivo substrate partitioning\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Effector metabolite in immune cells not identified\", \"In vivo balance between classical steroidogenesis and vitamin D/lumisterol hydroxylation unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 11, 17, 20, 31]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [17, 20, 25, 31]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [18, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [3, 18, 19, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 15, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [27, 28]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FDX1\", \"FDXR\", \"LONP1\", \"NR5A1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}